EXAS Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Exact Sciences Corp (EXAS) is not a strong buy at the moment for a beginner investor with a long-term strategy. The stock is trading close to its acquisition price of $105 per share, which limits upside potential. Additionally, the lack of significant trading signals, neutral technical indicators, and mixed financial performance suggest holding off on new investments in this stock.
The stock's MACD is negative and expanding, indicating bearish momentum. RSI is neutral at 64.753, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its pivot point of 103.036, with resistance at 103.498 and support at 102.573. Overall, technical indicators do not provide a strong buy signal.
Q4 2025 revenue exceeded expectations at $878.4 million, a 23.1% YoY increase, and gross margin improved to 70.11%, up 16.52% YoY.
The company reported a net loss of $86 million in Q4 2025, with EPS dropping by 90.36% YoY. Analysts have downgraded the stock to Hold or Neutral due to the acquisition agreement with Abbott at $105 per share, capping upside potential. Hedge funds are selling the stock, with a significant increase in selling activity (614.09% over the last quarter).
In Q4 2025, revenue increased by 23.12% YoY to $878.4 million, exceeding estimates. However, net income dropped by 90.06% YoY to -$85.96 million, and EPS fell by 90.36% YoY to -0.45. Gross margin improved to 70.11%, up 16.52% YoY.
Recent analyst ratings have downgraded the stock to Hold or Neutral, with a price target of $105 due to the acquisition agreement with Abbott. This indicates limited upside potential for the stock.
